Effect of progesterone on pregnancy rate of assisted reproduction

Comparison of oral progesterone with vaginal and subcutaneous progesterone for luteal phase support on pregnancy rate of infertile patients underwent intracytoplasmic sperm injection- Embryo transfer cycles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014071212494N2

Enrollment

300

Registered

2014-12-08

Start date

2014-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other complications associated with artificial fertilization. Noninflammatory disorders of female genital tract

Interventions

Intervention 1: Intervention: Duphaston(Oral Didrogesterone 10mg, Abbott, Netherland) 20mg , Twice daily until 12 weeks. Intervention 2: Intervention: Subcutaneous progesterone (Prolutex, 25mg, IBSA c

Treatment - Drugs

Intervention: Duphaston(Oral Didrogesterone 10mg, Abbott, Netherland) 20mg , Twice daily until 12 weeks.

Intervention: Subcutaneous progesterone (Prolutex, 25mg, IBSA company, Switzerland) daily injection until 12 weeks

Control: Vaginal suppository cyclogest,(A kind of vaginal progesterone, 400 mg, actover company,Britain)400mg twice daily until 12 weeks.

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria; Women at age 20-45 yearsold: Undervent intracytoplasmic sperm injection-Embryo trnsfer(ICSI-ET)(Fresh cycle): Have normal endometrial thickness(7-12) on embryo transfer day; Don't have any observational endometrial pathology enter in to the study. Exclusion criteria; Advanced endometriosis; Dense pelvic adhesion; Genital TB; Previous intracytoplasmic sperm injection( ICSI) cycle failures.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate. Timepoint: Five weeks after start of intervention. Method of measurement: Transvaginal ultrasonography.	—

Secondary

Measure	Time frame
Patients acceptance. Timepoint: Untill 12 weeks. Method of measurement: Questionare.;Miscariage rate. Timepoint: Until 24 weeks after start of intervention. Method of measurement: History, Physical exam, Ultrasonography.;Chemical pregnancy rate. Timepoint: Two weeks after embryo transfer. Method of measurement: Labratory kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Saharkhiz

Infertility & Reproductive Health Research Centre - Shahid Beheshti of Medical Science

saharkhiz1377@yahoo.com; www.irhrc.sbmu.ac.ir+98 21 2243 2558

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026